Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (October 2016)

30 slides from Zynerba Pharmaceuticals's investor presentation, Oct 13, 2016

  1. Slide 1: Disclaimer

    Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,

  2. Slide 2: Company Highlights

    Company Highlights 3 A clinical-stage specialty pharmaceutical company pioneering the development of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in patch and gel transdermal delivery, regulatory

  3. Slide 3: Robust Pipeline

    Robust Pipeline 4 Zynerba maintains global rights to all product candidates/indications ZYN002 patent protected through 2030 ZYN001 patent protected through 2031 Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 NDA Filing ZYN001 – THC Pro-Drug Patch ZYN002 – CBD Gel Refractory Epilep

  4. Slide 4: Multiple Near-term Milestones Expected

    Multiple Near-term Milestones Expected 5 ZYN001 THC Pro-Drug Patch ZYN002 CBD Gel Refractory Epilepsy in Adults (STAR 1 Trial) Osteoarthritis in Knees (STOP Trial) Fragile X Syndrome (Orphan Drug Designation) Fibromyalgia Peripheral Neuropathic Pain Phase 2 Initiated June Phase 2 Initiated August Ph

  5. Slide 5: ZYN002 – CBD Gel

    ZYN002 – CBD Gel First and only patent-protected permeation-enhanced synthetic cannabidiol gel formulated for transdermal delivery The permeation enhancer in ZYN002 increases the delivery of CBD through the layers of the epidermis and into the circulatory system 6 CBD Delivery

  6. Slide 6: Transdermal ZYN002 vs. Oral CBD

    Transdermal ZYN002 vs. Oral CBD 7 Potential Benefits of Transdermal ZYN002 vs. Oral CBD Avoids first-pass metabolism in the liver More consistent, controlled and sustained plasma level Avoids the GI tract Very low incidence of gastrointestinal events Fewer drug-drug interactions Lower incidence of n

  7. Slide 7: Transdermal CBD Avoids Degradation of CBD to THC

    Transdermal CBD Avoids Degradation of CBD to THC 8 In Vitro Study ZYN002 avoids the GI tract, maintains CBD at physiological pH and prevents degradation of CBD to THC CBD degraded to THC in simulated gastric fluid May lead to increased psychoactive effects from THC Study data (Merrick et al.) publis

  8. Slide 8: ZYN002 Phase 1 Trials

    Trials 1 day, 7 day, and 14 day trials Subjects 98 healthy volunteers (n= 70 ZYN002; n= 28 placebo) and 22 epilepsy patients (n=16 ZYN002; n=6 placebo) Dose Daily doses levels – 50 to 504 mg CBD in 1%, 2.5% and 4.2% concentrations Safety & Tolerability ZYN002 was safe and well-tolerated at all dose

  9. Slide 9: Why CBD in Refractory Epilepsy in Adults?

    Why CBD in Refractory Epilepsy in Adults? 10 * Data provided by Decision Resources Demonstrated anticonvulsant effects in multiple in vivo models of epilepsy Proven effective in reducing seizures in children and adults in third party trials Dravet syndrome Lennox-Gastaut syndrome Focal seizures Size

  10. Slide 10: ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy

    ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy 11 Lennox-Gastaut Syndrome Dravet Syndrome Refractory Epilepsy with Focal Seizures Patient Age 2 – 55 years old 2 – 18 years old 18 – 70 years old Brain Localization Multi-Foci Multi-Foci One or More Foci Seizure Type(s) Focal Ton

  11. Slide 11: Epilepsy Phase 2 Clinical Trial – Initiated June 2016

    Epilepsy Phase 2 Clinical Trial – Initiated June 2016 12 ZYN002 High Dose: 195 mg of CBD 4.2% gel every 12 hours for 12 weeks ZYN002 Low Dose: 97.5 mg of CBD 4.2% gel every 12 hours for 12 weeks Placebo every 12 hours for 12 weeks 8-week baseline period to assess seizure frequency and type STAR 1 (S

  12. Slide 12: Why ZYN002 in Osteoarthritis?

    Why ZYN002 in Osteoarthritis? 13 CBD modulates the vanilloid TRPV1 receptor which mediates antinociceptive and anti-inflammatory effects Mono-arthritic rat model provides proof of concept* ZYN002 was applied for four days after inducing arthritis in rats Significant reductions in: Swelling of knee j

  13. Slide 13: Osteoarthritis Phase 2 Clinical Trial – Initiated August 2016

    Osteoarthritis Phase 2 Clinical Trial – Initiated August 2016 14 ZYN002 High Dose: 250 mg of CBD 4.2% gel every 12 hours for 12 weeks ZYN002 Low Dose: 125 mg of CBD 4.2% gel every 12 hours for 12 weeks Placebo every 12 hours for 12 weeks 1-week Washout Period; 1-week Baseline Period STOP (Synthetic

  14. Slide 14: What is Fragile X Syndrome?

    What is Fragile X Syndrome? 15 Fragile X Syndrome Autism spectrum disorder Most common inherited intellectual disability ~71,000 patients in US Caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome Leads to dysregulation of the endocannabinoid pathway including th

  15. Slide 15: Why ZYN002 in Fragile X Syndrome?

    Why ZYN002 in Fragile X Syndrome? CBD may effectively treat Fragile X syndrome In mouse knock-out model, inhibition of the metabolism of 2-AG improves Fragile X syndrome symptoms CBD inhibits the metabolism of anandamide and 2-AG increasing availability of these cannabinoids CBD has strong anxiolyti

  16. Slide 16: Fragile X Syndrome Phase 2 Clinical Trial – Initiation Expected in 2H16

    Fragile X Syndrome Phase 2 Clinical Trial – Initiation Expected in 2H16 Open-label trial enrolling 16 patients aged 5 – 17 years old 12 weeks of dosing Outcome measures Anxiety, Depression and Mood Scale in FXS Aberrant Behavior Checklist Visual analog scale (VAS) for hyperactivity/impulsivity 17

  17. Slide 17: ZYN001 – THC Pro-Drug Patch

    ZYN001 – THC Pro-Drug Patch 18 Patent-protected synthetic D-glyceric acid ester-9-tetrahydrocannabinol in a transdermal patch ZYN001 is a pro-drug A drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different form through a no

  18. Slide 18: Why a Patch?

    Note: Based upon FDA approved patch products. These results are not indicative of any preclinical or clinical data for ZYN001. Why a Patch? 19 Requirement Purpose Non-oral Avoids first-pass metabolism with increased bioavailability and more consistent plasma levels Controlled More consistent, contro

  19. Slide 19: Why THC in Fibromyalgia?

    Multi-benefits of CB1 agonists Have an analgesic effect in chronic pain models Act at many sites along pain transmission pathways Nabilone (THC analogue) in patients with fibromyalgia Third-party 4-week, randomized, double-blind, placebo-controlled trial (N=40) — significant decreases in pain scores

  20. Slide 20: Why THC in Peripheral Neuropathic Pain?

    Third-party randomized, double-blind, placebo-controlled crossover trial in diabetic peripheral neuropathy (DPN) demonstrated that THC is effective in reducing neuropathic pain 16 patients with DPN received low (1% THC), medium (4% THC) or high (7% THC) dose of vaporized Cannabis and placebo in rand

  21. Slide 21: ZYN001 – THC Pro-Drug Patch Status

    ZYN001 – THC Pro-Drug Patch Status In vitro and in vivo studies to date show: Effective skin permeation with sustained delivery Non-mutagenic and non-genotoxic Safety pharmacology GLP studies Profile similar to THC GLP toxicology studies ongoing Expect to initiate Phase 1 2H2016 22 Note: Subject to

  22. Slide 22: ZYN001 Preliminary Phase 1 Clinical Plan

    ZYN001 – THC Pro-Drug Patch Preliminary Phase 1 Clinical Plan 23 Trial Patients Dosing PD Evaluations Timing Single Rising Dose Trial in Normal Subjects Pharmacokinetic profile and tolerability evaluation 32 healthy volunteers and 12 patients with fibromyalgia Single dose Cognition and attention (Tr

  23. Slide 23: ZYN001 Preliminary Phase 2 Clinical Plan

    24 Note: Subject to change due to further regulatory, clinical and other considerations. Trial Patients Dosing Primary Endpoint Timing Efficacy and Tolerability in Patients with Fibromyalgia Double-blind, placebo-controlled 120 patients 12 weeks Change from baseline in Fibromyalgia Impact Questionna

  24. Slide 24: Financial Overview: IPO, Cash and Shares Outstanding

    25 IPO August 2015 (NASDAQ: ZYNE) raised $42.1MM net Cash and cash equivalents as of June 30, 2016, $32.1MM Expected to fund Company through 2017 and five Phase 2 trials (Phase 3 Ready) Total shares outstanding as of June 30, 2016 was 9,199,919 shares No debt Cash Expected to Fund 5 Phase 2 Clinical

  25. Slide 25: Proven Leadership in Transdermal Drug Development

    Proven Leadership in Transdermal Drug Development 26 Armando Anido Chairman of the Board & Chief Executive Officer Terri Sebree President Jim Fickenscher CFO & VP Corp. Development Donna Gutterman, PharmD VP, Medical Nancy Tich, PhD VP, Clinical

  26. Slide 26: Scientific Advisory Board

    Jacqueline French, MD Professor of Neurology, NYU Langone Medical Center John Messenheimer, MD Consultant, Neurologist/Epileptologist, John Messenheimer PLLC Michael Rogawski, MD, PhD Professor of Neurology, UC Davis Center for Neuroscience Rodney Radtke, MD Professor of Neurology, Duke University M

  27. Slide 27: Company Highlights

    Company Highlights 28 A clinical-stage specialty pharmaceutical company pioneering the development of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in patch and gel transdermal delivery, regulatory

  28. Slide 28: Investor Relations

    Investor Relations 29 NASDAQ: ZYNE Analyst Coverage* Jefferies: Biren Amin, PhD Piper Jaffray: Charles C. Duncan, PhD Canaccord Genuity: Arlinda Lee, PhD Oppenheimer: Marcus Ho Roth: Michael Higgins H.C. Wainwright: Corey Davis, PhD * Note: Any opinions, estimates or forecasts regarding Zynerba Phar

  29. Slide 29: October 2016

    October 2016 A clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs

  30. Slide 30: Acclini ialty pharmaceutical

    Acclini ialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs October 2016

Zynerba Pharmaceuticals — Investor Presentation (October 2016) on 6ix